Acer Therapeutics ROA 2024

Mitä Acer Therapeutics tekee?

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel drugs for rare and life-threatening diseases. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts. The history of Acer Therapeutics began with an innovative strategy for rediscovering already approved drugs for new therapeutic applications. The company utilizes a "repurposing" technology, in which already approved drugs are reevaluated and further developed for the treatment of rare diseases. Acer Therapeutics' business model includes a combination of in-house research activities, strategic partnerships, and acquisitions. The company follows a portfolio strategy with a focus on rare diseases to develop a diversified pipeline of innovative medications. The various divisions of Acer Therapeutics focus on different therapeutic areas. Currently, the company is focused on the development of drugs for the treatment of rare anemia, severe lymphocytic leukemia, and narcolepsy. Acer Therapeutics' flagship product is EDSIVO, a medication for the treatment of arterial hypertension, a rare and life-threatening condition characterized by elevated blood pressure in the arteries. EDSIVO is currently approved in the United States and is under review in Europe. The company plans to further develop EDSIVO for the treatment of other rare diseases. Another important product of Acer Therapeutics is ACER-001, a medication for the treatment of the rare metabolic disorder urea cycle disorders. ACER-001 is an oral formulation of sodium phenylbutyrate and is intended to help patients regulate ammonia metabolism and alleviate symptoms. In recent years, Acer Therapeutics has also entered into several strategic partnerships and acquisitions to expand and strengthen its pipeline of rare diseases. In 2019, the company acquired biopharmaceutical specialist Celipheon, thereby expanding its portfolio to include drugs for the treatment of anemia and leukemia. Another important partner of Acer Therapeutics is Ultragenyx Pharmaceutical, a biopharmaceutical company specializing in the development of therapies for rare and ultra-rare diseases. The two companies have entered into a licensing agreement for ACER-001, in which Ultragenyx has exclusive rights for the commercialization of the medication in North America and Europe. Overall, Acer Therapeutics' business model and portfolio strategy have made it a key player in the rare disease sector. Through partnerships and acquisitions, it has expanded its pipeline and focused its research on various therapeutic areas. The company is currently in a growth phase and has the potential to bring more groundbreaking medications for rare diseases to the market in the future. Acer Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.